Document is current
Any future updates will be listed below
-
Authors
Ring, Sandra S.
Cupovic, Jovana
Onder, Lucas
Lütge, Mechthild https://orcid.org/0000-0001-9011-5319
Perez-Shibayama, Christian
Gil-Cruz, Cristina
Scandella, Elke
De Martin, Angelina
Mörbe, Urs https://orcid.org/0000-0001-8747-437X
Hartmann, Fabienne https://orcid.org/0000-0003-2247-2693
Wenger, Robert
Spiegl, Matthias https://orcid.org/0000-0003-3940-7791
Besse, Andrej
Bonilla, Weldy V.
Stemeseder, Felix
Schmidt, Sarah
Orlinger, Klaus K.
Krebs, Philippe https://orcid.org/0000-0003-4918-6654
Ludewig, Burkhard https://orcid.org/0000-0002-7685-573X
Flatz, Lukas
-
Funding
Funding for this research was provided by:
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (166500, 159188, 157448, 187189)
- License Information
-
More Information
Article History
Received: 9 December 2020
Accepted: 19 July 2021
First Online: 5 August 2021
Competing interests
: The authors declare the following competing interests. L.F. is a founder and shareholder of Hookipa Pharma Inc. F.S., S.S., and K.K.O. are employees and stock option holder of Hookipa Pharma, Inc. L.F., S.S.R, S.S., and K.K.O are listed as inventors of the patent entitled “Arenavirus particles to treat solid tumors” (patent number WO2018/185307 A1) describing the application of artLCMV vectors in the treatment of tumors. B.L., L.O., C.P.S., and C.G.C. are founders and shareholders of Stromal Therapeutics AG. S.S.R. is part-time employee of Stromal Therapeutics AG. The remaining authors declare no competing interests.
